Huffman L, Hedge G A
Life Sci. 1986 Dec 1;39(22):2143-50. doi: 10.1016/0024-3205(86)90365-6.
The effects of peptide HI (PHI), neuropeptide Y (NPY), and substance P (SP) on thyroid blood flow and hormone levels were studied in anesthetized rats. Regional blood flows were determined using radioactive microspheres. No change in heart rate or mean left ventricular pressure occurred during these neuropeptide infusions (0.625 micrograms iv over 2 min). PHI treatment resulted in a four-fold increase in thyroid blood flow. Blood flows to the pancreas and salivary gland also increased during PHI treatment. Infusions of NPY or SP did not significantly alter thyroid blood flow. However, SP decreased blood flow to the spleen and small intestine. These neuropeptides had no effect on blood flows to the adrenal, kidney, brain, heart, and adipose tissues. Following PHI, NPY, and SP infusions, plasma triiodothyronine and thyroxine levels were not different from values in saline-treated rats. This study demonstrates that PHI, like vasoactive intestinal peptide, is a potent thyroidal vasodilator at a dose that does not affect circulating thyroid hormone secretion.
在麻醉大鼠中研究了肽 HI（PHI）、神经肽 Y（NPY）和 P 物质（SP）对甲状腺血流和激素水平的影响。使用放射性微球测定局部血流。在这些神经肽输注期间（2 分钟内静脉注射 0.625 微克），心率或平均左心室压力未发生变化。PHI 处理导致甲状腺血流增加四倍。在 PHI 处理期间，胰腺和唾液腺的血流也增加。输注 NPY 或 SP 并未显著改变甲状腺血流。然而，SP 减少了脾脏和小肠的血流。这些神经肽对肾上腺、肾脏、大脑、心脏和脂肪组织的血流没有影响。在输注 PHI、NPY 和 SP 后，血浆三碘甲状腺原氨酸和甲状腺素水平与生理盐水处理大鼠的值没有差异。这项研究表明，PHI 与血管活性肠肽一样，在不影响循环甲状腺激素分泌的剂量下是一种有效的甲状腺血管扩张剂。
